Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

Exclusion Criteria20

• Hiatal hernia \>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)
• Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator
• Severe gastroparesis
• Previous bariatric or anti-reflux procedure
• Barrett's esophagus
• Subjects requiring mesh treatment at time of procedure
• Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator
• Subjects with pacemakers, implantable defibrillators, neurostimulators
• Portal hypertension or cirrhosis
• Chronic pancreatitis
• Active cancer treatment
• Inability to tolerate general anesthesia
• Uncontrollable coagulopathy
• Significant and uncontrolled inflammatory bowel disease
• Severe and/or uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.
• Suicidal ideation or unstable/untreated major depressive disorder within the past year
• Alcohol or substance use disorder within the past year.
• Pregnant or breastfeeding or planning pregnancy in the coming 24 months
• Diminished intellectual capacity to consent or follow pre- and post-surgery instructions
• History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.